Lumenis Ltd, an energy-based medical device company, has launched its new Digital Duet, claimed to be the first digital SLT-YAG system on the market, it was reported on Thursday.
The company said that Digital Duet takes gold-standard laser glaucoma treatment and posterior capsulotomy to the next level with the launch of advanced digital and connectivity capabilities, completely redefining the platform. The new Digital Duet streamlines workflow in the ophthalmology practice. Doctors can seamlessly generate reports and save data, images and video to the practice network and the electronic medical record, with no need for additional documentation or laser logs.
Dr Nathan M Radcliffe of the New York Eye and Ear Infirmary, New York City, said, 'The Digital Duet's digital imaging capabilities are allowing me to document pathologies. Also, I can now share images with my patients to help them understand their conditions and feel comfortable with therapy. It's exciting to get these totally new capabilities in a system with the enhanced energy control, visualisation and precision I need to achieve the outcomes I want for patients with glaucoma.'
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions